Novogene Co Ltd (688315)

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcriptome, isoform, direct RNA, prokaryotic RNA, and metatranscriptome sequencing; and single cell gene expression, single cell long road read transcriptome, and visium formalin-fixed paraffin-embedded spatial transcriptome solutions. It also provides epigenomic solutions comprising whole genome bisulfite, reduced representation bisulfite, chromatin immunoprecipitation, and RNA immunoprecipitation sequencing; premade library and proteomics services; clinical diagnostics services, such as clinical whole exome sequencing and clinical panels; biopharma services consisting of discovery and pre-clinical, translational and clinical, and companion diagnostics; and support services. In addition, the company offers sequencing platforms under the ILLUMINA, PACBIO, 10X GENOMICS, and NANOPORE brands; and basic scientific research services in life sciences, and medical research and technical services. Its services are used in cancer research, immuno-oncology agrigenomics, environment, food science, human microbiome, plant and animal microbiome, drug discovery and development, and rare and complex diseases applications. The company serves research universities, research institutes, hospitals, pharmaceutical research and development companies, and agricultural companies. Novogene Co., Ltd. was founded in 2011 and is headquartered in Beijing, China.